MPM BioVentures 2014, L.P. - Dec 10, 2024 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Stock symbol
TRDA
Transactions as of
Dec 10, 2024
Transactions value $
-$917,111
Form type
4
Date filed
12/12/2024, 05:00 PM
Previous filing
Jun 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Sale -$476K -22.9K -0.52% $20.77 4.4M Dec 10, 2024 See Footnote F1, F2, F3, F4
transaction TRDA Common Stock Sale -$441K -21.8K -0.49% $20.23 4.38M Dec 11, 2024 See Footnote F4, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold as follows: 10,415 by MPM BioVentures 2014, L.P. ("BV 2014"), 695 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 358 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10 688 by MPM BioVentures 2018, L.P. ("BV 2018"), 568 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 211 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
F2 Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.356 to $21.315 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3 The shares are held as follows: 1,999,261 by BV 2014, 133,347 by BV 2014(B), 68,816 by AM BV2014, 2,051,874 by BV 2018, 109,055 by BV 2018(B) and 40,496 by AM BV2018.
F4 Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5 The shares were sold as follows: 9,893 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014, 10,153 by BV 2018, 540 by BV 2018(B) and 200 by AM BV2018.
F6 Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.01 to $20.595 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F7 The shares are held as follows: 1,989,368 by BV 2014, 132,687 by BV 2014(B), 68,475 by AM BV2014, 2,041,721 by BV 2018, 108,515 by BV 2018(B) and 40,296 by AM BV2018.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.